AstraZeneca: lung cancer trial shows mixed results
(CercleFinance.com) - AstraZeneca's Imfinzi, in combination with chemotherapy, has confirmed a meaningful overall survival benefit for patients with extensive-stage small cell lung cancer in a Phase III trial, the drugmaker said on Tuesday.
However, a second immunotherapy belonging to AstraZeneca's, tremelimumab, did not meet its primary endpoint when added to Imfinzi, the company said.
A second experimental arm testing tremelimumab, which is a monoclonal antibody, added to Imfinzi and chemotherapies did not meet its primary endpoint of demonstrating a statistically significant improvement in overall survival, according to the final analysis of the Phase III trial.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
However, a second immunotherapy belonging to AstraZeneca's, tremelimumab, did not meet its primary endpoint when added to Imfinzi, the company said.
A second experimental arm testing tremelimumab, which is a monoclonal antibody, added to Imfinzi and chemotherapies did not meet its primary endpoint of demonstrating a statistically significant improvement in overall survival, according to the final analysis of the Phase III trial.
Copyright (c) 2020 CercleFinance.com. All rights reserved.